Troubled health care roll-up artist Valeant is like a bunch of “choir boys” when compared pharmaceutical concern Mallinckrodt, short seller Andrew Left of Citron Research said on CNBC Wednesday after the close, where he was confronted by the firm’s CEO. Left was short and vocal regarding Valeant, says its the tip of the iceberg Left is among a group of highly watched researchers who is perhaps best known for his short selling recommendations, particularly with regard to Valeant Pharmaceuticals. Left had talked the stock down before buying back his exposure. On October 2, ValueWalk reported on a Citron research piece that claimed “Valeant’s…
Mallinckrodt PLC CEO Confronts Short Seller Andrew Left But Doesn't Appear to Answer His Questions
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.